Parkman Healthcare Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Parkman Healthcare Partners’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-65,050	Closed	-$2.06M	–	100
2023 Q3	$2.06M	Buy	65,050 +2,640	+4%	+$72.3K	0.38%	71
2023 Q2	$1.61M	Buy	62,410 +292	+0.5%	+$7.77K	0.28%	82
2023 Q1	$1.49M	Buy	62,118 +9,364	+18%	+$213K	0.32%	67
2022 Q4	$1.03M	Buy	52,754 +10,359	+24%	+$205K	0.27%	72
2022 Q3	$891K	Buy	42,395 +10,381	+32%	+$250K	0.25%	75
2022 Q2	$623K	Buy	32,014 +1,660	+5%	+$39.2K	0.23%	66
2022 Q1	$668K	Buy	+30,354	New	+$619K	0.2%	73

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Parkman Healthcare Partners's MIRM Position: Q4 2023 in Review

Parkman Healthcare Partners sold out of Mirum Pharmaceuticals (MIRM) in Q4 2023, closing a stake of 65,050 shares — an estimated $2.06M sold.

Parkman Healthcare Partners first reported a position in MIRM in Q1 2022 and held it in 7 quarters. The position peaked at $2.06M in Q3 2023. 187 funds tracked by Wall St. Rank hold MIRM as of Q4 2023.

Parkman Healthcare Partners reported no remaining Mirum Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Parkman Healthcare Partners sold 65,050 Mirum Pharmaceuticals shares in Q4 2023, an estimated $2.06M.
Parkman Healthcare Partners first reported a position in Mirum Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Parkman Healthcare Partners's Mirum Pharmaceuticals position peaked at $2.06M in Q3 2023.
187 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2023.

Based on Parkman Healthcare Partners's 13F filing for Q4 2023, filed 14 Feb 2024.